EXCITING PARKINSON’S DISEASE TREATMENT NEWS

New York, NY, August 28, 2017 – The American Parkinson Disease Association is pleased to share with the Parkinson’s community the arrival of a new medication in the treatment arsenal to address Parkinson’s symptoms. Approved August 24 by the U.S. Food and Drug Administration is GOCOVRI™ (amantadine) developed by Adamas.  GOCOVRI is an extended release […]

Read More

Archived Webinar: Psychiatric Manifestations of Parkinson’s Disease

ARCHIVED: Free Webinar Hosted by University at Albany Aired on: Thursday, July 20, 2017 Watch Here University at Albany hosted a free live webcast for medical and public health professionals, featuring guest speaker Guy J. Schwartz, MD, the Assistant Clinical Professor of Neurology at Stony Brook University Medical Center. In depth, Guy discussed the psychiatric symptoms […]

Read More

Nationwide Movement to Help End Parkinson Disease: 2017 APDA Optimism Walk Series Launches to Raise Critical Funds and Awareness

Thousands Will Walk and Fundraise to Help People with Parkinson’s Live Life to the Fullest New York, NY, April 3, 2017 – With the launch of Parkinson’s Disease Awareness Month, the American Parkinson’s Disease Association (APDA) officially announces the schedule for the 2017 Optimism Walks — a nationwide movement to mobilize and inspire people to step […]

Read More

Eighty-Seven Organizations Call on Congress to Protect Medicaid

Source: Original Press Release through BusinessWire on March 20, 2017 04:28 PM Eastern Daylight Time BETHESDA, Md.–(BUSINESS WIRE)–Eighty-seven organizations issued a letter today calling on Congress to take a hard look at the likely significant and life-threatening consequences of the American Health Care Act on millions of patients. The organizations represent Americans with complex health […]

Read More

World Parkinson Congress 2016

2016 World Parkinson Congress Leadership Forum Before the 4th World Parkinson Congress officially kicked-off in Portland, Oregon nearly 200 Parkinson’s Organizational Partners gathered to network and learn from each other at the first ever WPC Leadership Forum. The Forum allowed PD Advocacy Leaders to talk about their outreach, fundraising, and educational efforts and to strategize […]

Read More

APDA Funded Researcher Published in Journal of Neuroscience – July 2016

APDA funded researcher published in Journal of Neuroscience – July 2016 APDA funded research demonstrates that alpha-synuclein inclusion formation in neurons can be blocked and that novel therapeutic compounds targeting this process by inhibiting LRRK2 kinase activity may slow progression of PD-associated pathology. In 2013 and 2014, APDA awarded research grants to Laura Vopicelli-Daley, PhD, […]

Read More

ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) is now available

The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis is now available through NUPLAZIDconnect™ Patient Access and Support Services The American Parkinson Disease Association is pleased to share the news that ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address […]

Read More

FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin)

FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis U.S. Commercial Launch Planned for June 2016 The American Parkinson Disease Association is pleased to share the news that ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative […]

Read More